Curcumin-ER prolonged subcutaneous delivery for the treatment of non-small cell lung cancer

Amalendu Prakash Ranjan, Anindita Mukerjee, Andrew Gdowski, Lawrence Helson, Annie Bouchard, Muhammed Majeed, Jamboor K. Vishwanatha

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)

Abstract

Non-small-cell lung cancer therapy is a challenge due to poor prognosis and low survival rate. There is an acute need for advanced therapies having higher drug efficacy, low immunogenicity and fewer side effects which will markedly improve patient compliance and quality of life of cancer patients. The purpose of this study was to develop a novel hybrid curcumin nanoformulation (Curcumin-ER) and evaluate the therapeutic efficacy of this formulation on a non-small cell lung cancer xenograft model. Use of curcumin, a natural anticancer agent, is majorly limited due to its poor aqueous solubility and hence it's low systemic bioavailability. In this paper, we carried out the nanoformulation of Curcumin-ER, optimized the formulation process and determined the anticancer effects of Curcumin-ER against human A549 non-small cell lung cancer using in vitro and in vivo studies. Xenograft tumors in nude mice were treated with 20 mg/kg subcutaneous injection of Curcumin-ER and liposomal curcumin (Lipocurc) twice a week for seven weeks. Results showed that tumor growth was suppressed by 52.1% by Curcumin-ER treatment and only 32.2% by Lipocurc compared to controls. Tumor sections were isolated from murine xenografts and histology and immunohistochemistry was performed. A decrease in expression of NFB-p65 subunit and proliferation marker, Ki-67 was observed in treated tumors. In addition, a potent anti-angiogenic effect, characterized by reduced expression of annexin A2 protein, was observed in treated tumors. These results establish the effectiveness of Curcumin-ER in regressing human non-small cell lung cancer growth in the xenograft model using subcutaneous route of administration. The therapeutic efficacy of Curcumin-ER highlights the potential of this hybrid nanoformulation in treating patients with non-small cell lung cancer.

Original languageEnglish
Pages (from-to)679-688
Number of pages10
JournalJournal of Biomedical Nanotechnology
Volume12
Issue number4
DOIs
StatePublished - 1 Apr 2016

Fingerprint

Curcumin
Non-Small Cell Lung Carcinoma
Tumors
Cells
Heterografts
Therapeutics
Histology
Neoplasms
Solubility
Proteins
Annexin A2
Subcutaneous Injections
Patient Compliance
Growth
Nude Mice
Antineoplastic Agents
Biological Availability
Survival Rate
Immunohistochemistry
Quality of Life

Keywords

  • A-549
  • Curcumin
  • Curcumin-ER
  • Lipid-Polymer Nanoparticle
  • Non-Small Cell Lung Cancer

Cite this

Ranjan, Amalendu Prakash ; Mukerjee, Anindita ; Gdowski, Andrew ; Helson, Lawrence ; Bouchard, Annie ; Majeed, Muhammed ; Vishwanatha, Jamboor K. / Curcumin-ER prolonged subcutaneous delivery for the treatment of non-small cell lung cancer. In: Journal of Biomedical Nanotechnology. 2016 ; Vol. 12, No. 4. pp. 679-688.
@article{436990872df84598aa08c208935c92df,
title = "Curcumin-ER prolonged subcutaneous delivery for the treatment of non-small cell lung cancer",
abstract = "Non-small-cell lung cancer therapy is a challenge due to poor prognosis and low survival rate. There is an acute need for advanced therapies having higher drug efficacy, low immunogenicity and fewer side effects which will markedly improve patient compliance and quality of life of cancer patients. The purpose of this study was to develop a novel hybrid curcumin nanoformulation (Curcumin-ER) and evaluate the therapeutic efficacy of this formulation on a non-small cell lung cancer xenograft model. Use of curcumin, a natural anticancer agent, is majorly limited due to its poor aqueous solubility and hence it's low systemic bioavailability. In this paper, we carried out the nanoformulation of Curcumin-ER, optimized the formulation process and determined the anticancer effects of Curcumin-ER against human A549 non-small cell lung cancer using in vitro and in vivo studies. Xenograft tumors in nude mice were treated with 20 mg/kg subcutaneous injection of Curcumin-ER and liposomal curcumin (Lipocurc) twice a week for seven weeks. Results showed that tumor growth was suppressed by 52.1{\%} by Curcumin-ER treatment and only 32.2{\%} by Lipocurc compared to controls. Tumor sections were isolated from murine xenografts and histology and immunohistochemistry was performed. A decrease in expression of NFB-p65 subunit and proliferation marker, Ki-67 was observed in treated tumors. In addition, a potent anti-angiogenic effect, characterized by reduced expression of annexin A2 protein, was observed in treated tumors. These results establish the effectiveness of Curcumin-ER in regressing human non-small cell lung cancer growth in the xenograft model using subcutaneous route of administration. The therapeutic efficacy of Curcumin-ER highlights the potential of this hybrid nanoformulation in treating patients with non-small cell lung cancer.",
keywords = "A-549, Curcumin, Curcumin-ER, Lipid-Polymer Nanoparticle, Non-Small Cell Lung Cancer",
author = "Ranjan, {Amalendu Prakash} and Anindita Mukerjee and Andrew Gdowski and Lawrence Helson and Annie Bouchard and Muhammed Majeed and Vishwanatha, {Jamboor K.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1166/jbn.2016.2207",
language = "English",
volume = "12",
pages = "679--688",
journal = "Journal of Biomedical Nanotechnology",
issn = "1550-7033",
publisher = "American Scientific Publishers",
number = "4",

}

Curcumin-ER prolonged subcutaneous delivery for the treatment of non-small cell lung cancer. / Ranjan, Amalendu Prakash; Mukerjee, Anindita; Gdowski, Andrew; Helson, Lawrence; Bouchard, Annie; Majeed, Muhammed; Vishwanatha, Jamboor K.

In: Journal of Biomedical Nanotechnology, Vol. 12, No. 4, 01.04.2016, p. 679-688.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Curcumin-ER prolonged subcutaneous delivery for the treatment of non-small cell lung cancer

AU - Ranjan, Amalendu Prakash

AU - Mukerjee, Anindita

AU - Gdowski, Andrew

AU - Helson, Lawrence

AU - Bouchard, Annie

AU - Majeed, Muhammed

AU - Vishwanatha, Jamboor K.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Non-small-cell lung cancer therapy is a challenge due to poor prognosis and low survival rate. There is an acute need for advanced therapies having higher drug efficacy, low immunogenicity and fewer side effects which will markedly improve patient compliance and quality of life of cancer patients. The purpose of this study was to develop a novel hybrid curcumin nanoformulation (Curcumin-ER) and evaluate the therapeutic efficacy of this formulation on a non-small cell lung cancer xenograft model. Use of curcumin, a natural anticancer agent, is majorly limited due to its poor aqueous solubility and hence it's low systemic bioavailability. In this paper, we carried out the nanoformulation of Curcumin-ER, optimized the formulation process and determined the anticancer effects of Curcumin-ER against human A549 non-small cell lung cancer using in vitro and in vivo studies. Xenograft tumors in nude mice were treated with 20 mg/kg subcutaneous injection of Curcumin-ER and liposomal curcumin (Lipocurc) twice a week for seven weeks. Results showed that tumor growth was suppressed by 52.1% by Curcumin-ER treatment and only 32.2% by Lipocurc compared to controls. Tumor sections were isolated from murine xenografts and histology and immunohistochemistry was performed. A decrease in expression of NFB-p65 subunit and proliferation marker, Ki-67 was observed in treated tumors. In addition, a potent anti-angiogenic effect, characterized by reduced expression of annexin A2 protein, was observed in treated tumors. These results establish the effectiveness of Curcumin-ER in regressing human non-small cell lung cancer growth in the xenograft model using subcutaneous route of administration. The therapeutic efficacy of Curcumin-ER highlights the potential of this hybrid nanoformulation in treating patients with non-small cell lung cancer.

AB - Non-small-cell lung cancer therapy is a challenge due to poor prognosis and low survival rate. There is an acute need for advanced therapies having higher drug efficacy, low immunogenicity and fewer side effects which will markedly improve patient compliance and quality of life of cancer patients. The purpose of this study was to develop a novel hybrid curcumin nanoformulation (Curcumin-ER) and evaluate the therapeutic efficacy of this formulation on a non-small cell lung cancer xenograft model. Use of curcumin, a natural anticancer agent, is majorly limited due to its poor aqueous solubility and hence it's low systemic bioavailability. In this paper, we carried out the nanoformulation of Curcumin-ER, optimized the formulation process and determined the anticancer effects of Curcumin-ER against human A549 non-small cell lung cancer using in vitro and in vivo studies. Xenograft tumors in nude mice were treated with 20 mg/kg subcutaneous injection of Curcumin-ER and liposomal curcumin (Lipocurc) twice a week for seven weeks. Results showed that tumor growth was suppressed by 52.1% by Curcumin-ER treatment and only 32.2% by Lipocurc compared to controls. Tumor sections were isolated from murine xenografts and histology and immunohistochemistry was performed. A decrease in expression of NFB-p65 subunit and proliferation marker, Ki-67 was observed in treated tumors. In addition, a potent anti-angiogenic effect, characterized by reduced expression of annexin A2 protein, was observed in treated tumors. These results establish the effectiveness of Curcumin-ER in regressing human non-small cell lung cancer growth in the xenograft model using subcutaneous route of administration. The therapeutic efficacy of Curcumin-ER highlights the potential of this hybrid nanoformulation in treating patients with non-small cell lung cancer.

KW - A-549

KW - Curcumin

KW - Curcumin-ER

KW - Lipid-Polymer Nanoparticle

KW - Non-Small Cell Lung Cancer

UR - http://www.scopus.com/inward/record.url?scp=84961700389&partnerID=8YFLogxK

U2 - 10.1166/jbn.2016.2207

DO - 10.1166/jbn.2016.2207

M3 - Article

VL - 12

SP - 679

EP - 688

JO - Journal of Biomedical Nanotechnology

JF - Journal of Biomedical Nanotechnology

SN - 1550-7033

IS - 4

ER -